Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BRTX 
BioRestorative Therapies Inc (BRTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/11/2025: BRTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $13
1 Year Target Price $13
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -46.72% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.50M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 2 | Beta 76.59 | 52 Weeks Range 1.21 - 2.55 | Updated Date 06/30/2025 |
52 Weeks Range 1.21 - 2.55 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -19230.14% |
Management Effectiveness
Return on Assets (TTM) -54.17% | Return on Equity (TTM) -117.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -948770 | Price to Sales(TTM) 31.97 |
Enterprise Value -948770 | Price to Sales(TTM) 31.97 | ||
Enterprise Value to Revenue 5.06 | Enterprise Value to EBITDA 0.13 | Shares Outstanding 7504780 | Shares Floating 4922685 |
Shares Outstanding 7504780 | Shares Floating 4922685 | ||
Percent Insiders 25.54 | Percent Institutions 12.62 |
Analyst Ratings
Rating 2 | Target Price 13 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BioRestorative Therapies Inc
Company Overview
History and Background
BioRestorative Therapies, Inc. was founded in 2006. It is a biotechnology company focused on the development of therapeutic products and platforms utilizing cell and tissue protocols, primarily involving adult stem cells. The company is still in the clinical stage and hasn't achieved commercialization yet. Milestones include advancing their disc/spine and metabolic disease (diabetes) programs into clinical trials.
Core Business Areas
- Disc/Spine Program (BRTX-100): Utilizes autologous cultured disc progenitor cells (cdPCs) to treat chronic lumbar disc disease (CLDD). Currently in clinical trials. Aims to regenerate degenerated discs and alleviate pain.
- Metabolic Disease Program (ThermoStem): Utilizes autologous brown adipose tissue (BAT) derived stem cells to treat metabolic disorders, particularly diabetes. Aims to improve metabolic function and reduce reliance on insulin.
Leadership and Structure
The leadership team includes Lance Alstodt (CEO), Ryan D. Murphy (CFO). The organizational structure is typical of a clinical-stage biotechnology company, with departments focused on research and development, clinical operations, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- BRTX-100: An autologous cell therapy targeting chronic lumbar disc disease (CLDD). Currently in Phase 2 clinical trials. Market share is currently 0% due to not being approved. Competitors include companies developing pain management solutions for CLDD and surgical interventions for severe cases.
- ThermoStem: An autologous cell therapy targeting metabolic disorders, including type 2 diabetes. Currently undergoing development. Market share is currently 0% due to not being approved. Competitors include companies developing insulin therapies, GLP-1 receptor agonists, and other diabetes management solutions.
Market Dynamics
Industry Overview
The regenerative medicine industry is growing, driven by increasing demand for innovative therapies and advances in cell and gene therapy technologies. The market is competitive, with numerous companies developing cell-based therapies for various indications.
Positioning
BioRestorative Therapies is positioned as a clinical-stage biotechnology company focused on developing cell therapies for unmet medical needs in disc/spine disease and metabolic disorders. Its competitive advantage lies in its proprietary cell therapy platforms and clinical trial progress.
Total Addressable Market (TAM)
The TAM for CLDD and type 2 diabetes is substantial, potentially reaching billions of dollars annually. BRTX is positioned to capture a share if approved, dependent on efficacy and pricing. ThermoStem addresses a similarly massive potential market in metabolic disorders.
Upturn SWOT Analysis
Strengths
- Proprietary cell therapy platforms
- Clinical-stage programs with promising early results
- Experienced management team
- Autologous approach potentially reduces risk of immune rejection
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- No approved products generating revenue
- Small Market capitalization and significant share dilution
Opportunities
- Positive clinical trial outcomes could lead to regulatory approval and commercialization
- Partnerships with larger pharmaceutical companies could provide funding and expertise
- Expansion of pipeline to target other indications
- Advancements in cell therapy manufacturing could reduce costs
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from other cell therapy companies and established therapies
- Manufacturing challenges and scalability issues
Competitors and Market Share
Key Competitors
- MESO
- CRIS
- VCEL
Competitive Landscape
BioRestorative Therapies faces significant competition from larger, more established companies with greater financial resources and approved products. It must differentiate itself through clinical trial success and innovative technologies.
Growth Trajectory and Initiatives
Historical Growth: No revenue growth due to the company's pre-commercial stage.
Future Projections: Future growth depends on positive clinical trial results, regulatory approval, and successful commercialization of its products. Analyst estimates are highly speculative at this stage.
Recent Initiatives: Focus on advancing BRTX-100 and ThermoStem through clinical trials. Seeking partnerships to secure funding and expertise.
Summary
BioRestorative Therapies is a high-risk, high-reward clinical-stage biotech company. Its strength lies in its cell therapy platforms. It faces challenges related to funding, clinical trial success, and competition. Future success depends on positive clinical trial results and regulatory approvals. The current financial state makes it vulnerable without external funding or positive catalyst.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Yahoo Finance
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioRestorative Therapies Inc
Exchange NASDAQ | Headquaters Melville, NY, United States | ||
IPO Launch date 2007-07-27 | Chairman of the Board, President & CEO Mr. Lance Alstodt | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://www.biorestorative.com |
Full time employees 11 | Website https://www.biorestorative.com | ||
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.